CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma

As an immune checkpoint that suppresses antitumor immunity, CD276 is a potential therapeutic target for cancer immunotherapy. However, the role of CD276 in esophageal squamous cell carcinoma (ESCC) has not been thoroughly examined. A greater understanding of the regulatory mechanism of CD276 may imp...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of gastrointestinal oncology 2021-02, Vol.12 (1), p.38-51
Hauptverfasser: Yue, Guangxing, Tang, Jingwen, Zhang, Lihan, Niu, Hong, Li, Huahua, Luo, Suxia
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 51
container_issue 1
container_start_page 38
container_title Journal of gastrointestinal oncology
container_volume 12
creator Yue, Guangxing
Tang, Jingwen
Zhang, Lihan
Niu, Hong
Li, Huahua
Luo, Suxia
description As an immune checkpoint that suppresses antitumor immunity, CD276 is a potential therapeutic target for cancer immunotherapy. However, the role of CD276 in esophageal squamous cell carcinoma (ESCC) has not been thoroughly examined. A greater understanding of the regulatory mechanism of CD276 may improve the clinical response and efficacy of cancer immunotherapy. The expression of CD276 was measured by qRT-PCR, IHC and flow cytometry analysis. T cell infiltration in ESCC was measured by qRT-PCR and immunofluorescence analysis. The regulation function of CD276 in glucose metabolism was examined by metabolism assays, western blotting and small molecule inhibitors. Transfection was used for gene editing. The oncogenic function of CD276 was examined in vivo by CAR-T cell therapy model. Based on our findings, CD276 regulated the expression of the gene in ESCC. Overexpression of CD276 induced the phosphorylation of PKM2 by the STAT3 signalling pathway to promote glucose metabolism in tumors. The accumulation of lactic acid in the tumor microenvironment has been reported to regulate the immune cells, particularly CD8+ T cells. We further analyzed the effect of CD276 on the function of T cells. Chimeric antigen receptor T cells (CAR-T) targeting human epidermal growth factor receptor 2 (HER2) were used as effector cells to detect the effect of CD276 on immunotherapy. The therapeutic effects of CAR-T cells were markedly limited by CD276 overexpression. Our results are the first to show that tumor-derived CD276 supports disease progression. Overexpression of CD276 promoted glucose metabolism in tumor and inhibited the function of CD8+ T cells. Therefore, strategies targeting CD276 might improve the response to cancer immunotherapy of ESCC patients.
doi_str_mv 10.21037/jgo-21-50
format Article
fullrecord <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7944158</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2501254182</sourcerecordid><originalsourceid>FETCH-LOGICAL-c378t-777b9e623c8bfb3373829859e406d1c8367efd67aa11e28edff0598344536c273</originalsourceid><addsrcrecordid>eNpVkVtLxDAQhYMorqz74g-QPIpQzaVpkhdB1issCLKCbyHNpjXSNt2kFfbfG91VdF5mYD7OnOEAcILRBcGI8sv32mcEZwztgSNCsMwKLl_304y4yAoh8QTMYnxHqXLJECOHYEIpRyIn9Ai08xvCCxjHvg82Rhvh_Po5W0JjmwZWY2cG5ztYbmAffOsH19VwGFsftkDdbIxvNtFF6Dpoo-_fdG11A-N61K0f4xYzOhjX-VYfg4NKN9HOdn0KXu5ul_OHbPF0_zi_XmSGcjFknPNS2oJQI8qqTGapIFIwaXNUrLARtOC2WhVca4wtEXZVVYhJQfOc0cIQTqfgaqvbj2VrV8Z2Q9CN6oNrddgor536v-ncm6r9h-IyzzETSeBsJxD8erRxUK2LX7_ozqa3FGEIE5ZjQRJ6vkVN8DEGW_2ewUh9R6RSRGlSDCX49K-xX_QnEPoJfgSN1A</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2501254182</pqid></control><display><type>article</type><title>CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><creator>Yue, Guangxing ; Tang, Jingwen ; Zhang, Lihan ; Niu, Hong ; Li, Huahua ; Luo, Suxia</creator><creatorcontrib>Yue, Guangxing ; Tang, Jingwen ; Zhang, Lihan ; Niu, Hong ; Li, Huahua ; Luo, Suxia</creatorcontrib><description>As an immune checkpoint that suppresses antitumor immunity, CD276 is a potential therapeutic target for cancer immunotherapy. However, the role of CD276 in esophageal squamous cell carcinoma (ESCC) has not been thoroughly examined. A greater understanding of the regulatory mechanism of CD276 may improve the clinical response and efficacy of cancer immunotherapy. The expression of CD276 was measured by qRT-PCR, IHC and flow cytometry analysis. T cell infiltration in ESCC was measured by qRT-PCR and immunofluorescence analysis. The regulation function of CD276 in glucose metabolism was examined by metabolism assays, western blotting and small molecule inhibitors. Transfection was used for gene editing. The oncogenic function of CD276 was examined in vivo by CAR-T cell therapy model. Based on our findings, CD276 regulated the expression of the gene in ESCC. Overexpression of CD276 induced the phosphorylation of PKM2 by the STAT3 signalling pathway to promote glucose metabolism in tumors. The accumulation of lactic acid in the tumor microenvironment has been reported to regulate the immune cells, particularly CD8+ T cells. We further analyzed the effect of CD276 on the function of T cells. Chimeric antigen receptor T cells (CAR-T) targeting human epidermal growth factor receptor 2 (HER2) were used as effector cells to detect the effect of CD276 on immunotherapy. The therapeutic effects of CAR-T cells were markedly limited by CD276 overexpression. Our results are the first to show that tumor-derived CD276 supports disease progression. Overexpression of CD276 promoted glucose metabolism in tumor and inhibited the function of CD8+ T cells. Therefore, strategies targeting CD276 might improve the response to cancer immunotherapy of ESCC patients.</description><identifier>ISSN: 2078-6891</identifier><identifier>EISSN: 2219-679X</identifier><identifier>DOI: 10.21037/jgo-21-50</identifier><identifier>PMID: 33708423</identifier><language>eng</language><publisher>China: AME Publishing Company</publisher><subject>Original</subject><ispartof>Journal of gastrointestinal oncology, 2021-02, Vol.12 (1), p.38-51</ispartof><rights>2021 Journal of Gastrointestinal Oncology. All rights reserved.</rights><rights>2021 Journal of Gastrointestinal Oncology. All rights reserved. 2021 Journal of Gastrointestinal Oncology.</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c378t-777b9e623c8bfb3373829859e406d1c8367efd67aa11e28edff0598344536c273</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944158/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7944158/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,723,776,780,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33708423$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yue, Guangxing</creatorcontrib><creatorcontrib>Tang, Jingwen</creatorcontrib><creatorcontrib>Zhang, Lihan</creatorcontrib><creatorcontrib>Niu, Hong</creatorcontrib><creatorcontrib>Li, Huahua</creatorcontrib><creatorcontrib>Luo, Suxia</creatorcontrib><title>CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma</title><title>Journal of gastrointestinal oncology</title><addtitle>J Gastrointest Oncol</addtitle><description>As an immune checkpoint that suppresses antitumor immunity, CD276 is a potential therapeutic target for cancer immunotherapy. However, the role of CD276 in esophageal squamous cell carcinoma (ESCC) has not been thoroughly examined. A greater understanding of the regulatory mechanism of CD276 may improve the clinical response and efficacy of cancer immunotherapy. The expression of CD276 was measured by qRT-PCR, IHC and flow cytometry analysis. T cell infiltration in ESCC was measured by qRT-PCR and immunofluorescence analysis. The regulation function of CD276 in glucose metabolism was examined by metabolism assays, western blotting and small molecule inhibitors. Transfection was used for gene editing. The oncogenic function of CD276 was examined in vivo by CAR-T cell therapy model. Based on our findings, CD276 regulated the expression of the gene in ESCC. Overexpression of CD276 induced the phosphorylation of PKM2 by the STAT3 signalling pathway to promote glucose metabolism in tumors. The accumulation of lactic acid in the tumor microenvironment has been reported to regulate the immune cells, particularly CD8+ T cells. We further analyzed the effect of CD276 on the function of T cells. Chimeric antigen receptor T cells (CAR-T) targeting human epidermal growth factor receptor 2 (HER2) were used as effector cells to detect the effect of CD276 on immunotherapy. The therapeutic effects of CAR-T cells were markedly limited by CD276 overexpression. Our results are the first to show that tumor-derived CD276 supports disease progression. Overexpression of CD276 promoted glucose metabolism in tumor and inhibited the function of CD8+ T cells. Therefore, strategies targeting CD276 might improve the response to cancer immunotherapy of ESCC patients.</description><subject>Original</subject><issn>2078-6891</issn><issn>2219-679X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNpVkVtLxDAQhYMorqz74g-QPIpQzaVpkhdB1issCLKCbyHNpjXSNt2kFfbfG91VdF5mYD7OnOEAcILRBcGI8sv32mcEZwztgSNCsMwKLl_304y4yAoh8QTMYnxHqXLJECOHYEIpRyIn9Ai08xvCCxjHvg82Rhvh_Po5W0JjmwZWY2cG5ztYbmAffOsH19VwGFsftkDdbIxvNtFF6Dpoo-_fdG11A-N61K0f4xYzOhjX-VYfg4NKN9HOdn0KXu5ul_OHbPF0_zi_XmSGcjFknPNS2oJQI8qqTGapIFIwaXNUrLARtOC2WhVca4wtEXZVVYhJQfOc0cIQTqfgaqvbj2VrV8Z2Q9CN6oNrddgor536v-ncm6r9h-IyzzETSeBsJxD8erRxUK2LX7_ozqa3FGEIE5ZjQRJ6vkVN8DEGW_2ewUh9R6RSRGlSDCX49K-xX_QnEPoJfgSN1A</recordid><startdate>202102</startdate><enddate>202102</enddate><creator>Yue, Guangxing</creator><creator>Tang, Jingwen</creator><creator>Zhang, Lihan</creator><creator>Niu, Hong</creator><creator>Li, Huahua</creator><creator>Luo, Suxia</creator><general>AME Publishing Company</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>202102</creationdate><title>CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma</title><author>Yue, Guangxing ; Tang, Jingwen ; Zhang, Lihan ; Niu, Hong ; Li, Huahua ; Luo, Suxia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c378t-777b9e623c8bfb3373829859e406d1c8367efd67aa11e28edff0598344536c273</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Original</topic><toplevel>online_resources</toplevel><creatorcontrib>Yue, Guangxing</creatorcontrib><creatorcontrib>Tang, Jingwen</creatorcontrib><creatorcontrib>Zhang, Lihan</creatorcontrib><creatorcontrib>Niu, Hong</creatorcontrib><creatorcontrib>Li, Huahua</creatorcontrib><creatorcontrib>Luo, Suxia</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of gastrointestinal oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yue, Guangxing</au><au>Tang, Jingwen</au><au>Zhang, Lihan</au><au>Niu, Hong</au><au>Li, Huahua</au><au>Luo, Suxia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma</atitle><jtitle>Journal of gastrointestinal oncology</jtitle><addtitle>J Gastrointest Oncol</addtitle><date>2021-02</date><risdate>2021</risdate><volume>12</volume><issue>1</issue><spage>38</spage><epage>51</epage><pages>38-51</pages><issn>2078-6891</issn><eissn>2219-679X</eissn><abstract>As an immune checkpoint that suppresses antitumor immunity, CD276 is a potential therapeutic target for cancer immunotherapy. However, the role of CD276 in esophageal squamous cell carcinoma (ESCC) has not been thoroughly examined. A greater understanding of the regulatory mechanism of CD276 may improve the clinical response and efficacy of cancer immunotherapy. The expression of CD276 was measured by qRT-PCR, IHC and flow cytometry analysis. T cell infiltration in ESCC was measured by qRT-PCR and immunofluorescence analysis. The regulation function of CD276 in glucose metabolism was examined by metabolism assays, western blotting and small molecule inhibitors. Transfection was used for gene editing. The oncogenic function of CD276 was examined in vivo by CAR-T cell therapy model. Based on our findings, CD276 regulated the expression of the gene in ESCC. Overexpression of CD276 induced the phosphorylation of PKM2 by the STAT3 signalling pathway to promote glucose metabolism in tumors. The accumulation of lactic acid in the tumor microenvironment has been reported to regulate the immune cells, particularly CD8+ T cells. We further analyzed the effect of CD276 on the function of T cells. Chimeric antigen receptor T cells (CAR-T) targeting human epidermal growth factor receptor 2 (HER2) were used as effector cells to detect the effect of CD276 on immunotherapy. The therapeutic effects of CAR-T cells were markedly limited by CD276 overexpression. Our results are the first to show that tumor-derived CD276 supports disease progression. Overexpression of CD276 promoted glucose metabolism in tumor and inhibited the function of CD8+ T cells. Therefore, strategies targeting CD276 might improve the response to cancer immunotherapy of ESCC patients.</abstract><cop>China</cop><pub>AME Publishing Company</pub><pmid>33708423</pmid><doi>10.21037/jgo-21-50</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2078-6891
ispartof Journal of gastrointestinal oncology, 2021-02, Vol.12 (1), p.38-51
issn 2078-6891
2219-679X
language eng
recordid cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7944158
source Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central
subjects Original
title CD276 suppresses CAR-T cell function by promoting tumor cell glycolysis in esophageal squamous cell carcinoma
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-14T19%3A53%3A08IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=CD276%20suppresses%20CAR-T%20cell%20function%20by%20promoting%20tumor%20cell%20glycolysis%20in%20esophageal%20squamous%20cell%20carcinoma&rft.jtitle=Journal%20of%20gastrointestinal%20oncology&rft.au=Yue,%20Guangxing&rft.date=2021-02&rft.volume=12&rft.issue=1&rft.spage=38&rft.epage=51&rft.pages=38-51&rft.issn=2078-6891&rft.eissn=2219-679X&rft_id=info:doi/10.21037/jgo-21-50&rft_dat=%3Cproquest_pubme%3E2501254182%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2501254182&rft_id=info:pmid/33708423&rfr_iscdi=true